{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,13]],"date-time":"2026-09-13T03:33:35Z","timestamp":1789270415384,"version":"build-2803163510"},"reference-count":47,"publisher":"Elsevier BV","issue":"3","license":[{"start":{"date-parts":[[2025,9,1]],"date-time":"2025-09-01T00:00:00Z","timestamp":1756684800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2025,9,1]],"date-time":"2025-09-01T00:00:00Z","timestamp":1756684800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","jaad.org","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Journal of the American Academy of Dermatology"],"published-print":{"date-parts":[[2025,9]]},"DOI":"10.1016\/j.jaad.2025.05.1401","type":"journal-article","created":{"date-parts":[[2025,5,21]],"date-time":"2025-05-21T12:05:24Z","timestamp":1747829124000},"page":"724-732","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":9,"title":["Cutaneous malignancy after biologic therapy for inflammatory disease: An active comparator, retrospective cohort study"],"prefix":"10.1016","volume":"93","author":[{"given":"Kyle C.","family":"Lauck","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Areeba","family":"Ahmed","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Michael J.","family":"Davis","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"M. Laurin","family":"Council","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kishwer","family":"Nehal","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Murad","family":"Alam","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"issue":"1","key":"10.1016\/j.jaad.2025.05.1401_bib1","doi-asserted-by":"crossref","first-page":"98","DOI":"10.1186\/1476-4598-12-98","article-title":"Cancer risk in immune-mediated inflammatory diseases (IMID)","volume":"12","author":"Beyaert","year":"2013","journal-title":"Mol Cancer"},{"issue":"1","key":"10.1016\/j.jaad.2025.05.1401_bib2","doi-asserted-by":"crossref","first-page":"3","DOI":"10.1111\/cei.13101","article-title":"Genetics of immune-mediated inflammatory diseases","volume":"193","author":"David","year":"2018","journal-title":"Clin Exp Immunol"},{"issue":"2 Pt 1","key":"10.1016\/j.jaad.2025.05.1401_bib3","doi-asserted-by":"crossref","first-page":"307","DOI":"10.1016\/S0190-9622(00)90154-3","article-title":"Skin cancer in kidney and heart transplant recipients and different long-term immunosuppressive therapy regimens","volume":"42","author":"Jensen","year":"2000","journal-title":"J Am Acad Dermatol"},{"issue":"15","key":"10.1016\/j.jaad.2025.05.1401_bib4","doi-asserted-by":"crossref","first-page":"11369","DOI":"10.1074\/jbc.M109.028142","article-title":"Immunosuppressive cyclosporin A activates AKT in keratinocytes through PTEN suppression: implications in skin carcinogenesis","volume":"285","author":"Han","year":"2010","journal-title":"J Biol Chem"},{"issue":"9","key":"10.1016\/j.jaad.2025.05.1401_bib5","doi-asserted-by":"crossref","first-page":"1187","DOI":"10.1097\/TP.0b013e318187bab0","article-title":"Comparison of sirolimus plus tacrolimus versus sirolimus plus cyclosporine in high-risk renal allograft recipients: results from an open-label, randomized trial","volume":"86","author":"Gaber","year":"2008","journal-title":"Transplantation"},{"issue":"6","key":"10.1016\/j.jaad.2025.05.1401_bib6","doi-asserted-by":"crossref","first-page":"636","DOI":"10.1097\/01.TP.0000437669.93963.8E","article-title":"Long-term follow-up of a phase III clinical trial comparing tacrolimus extended-release\/MMF, tacrolimus\/MMF, and cyclosporine\/MMF in de novo kidney transplant recipients","volume":"97","author":"Silva","year":"2014","journal-title":"Transplantation"},{"issue":"2","key":"10.1016\/j.jaad.2025.05.1401_bib7","doi-asserted-by":"crossref","first-page":"565","DOI":"10.1111\/ajt.13596","article-title":"Immunosuppressive medications and squamous cell skin carcinoma: nested case-control study within the skin cancer after organ transplant (SCOT) cohort","volume":"16","author":"Coghill","year":"2016","journal-title":"Am J Transplant"},{"issue":"9287","key":"10.1016\/j.jaad.2025.05.1401_bib8","doi-asserted-by":"crossref","first-page":"1042","DOI":"10.1016\/S0140-6736(01)06179-7","article-title":"Squamous-cell cancer of the skin in patients given PUVA and ciclosporin: nested cohort crossover study","volume":"358","author":"Marcil","year":"2001","journal-title":"Lancet"},{"issue":"4","key":"10.1016\/j.jaad.2025.05.1401_bib9","doi-asserted-by":"crossref","first-page":"290","DOI":"10.3109\/09546634.2011.590792","article-title":"Cyclosporine and skin cancer: an international dermatologic perspective over 25 years of experience. A comprehensive review and pursuit to define safe use of cyclosporine in dermatology","volume":"23","author":"Muellenhoff","year":"2012","journal-title":"J Dermatolog Treat"},{"issue":"12","key":"10.1016\/j.jaad.2025.05.1401_bib10","doi-asserted-by":"crossref","first-page":"3490","DOI":"10.1111\/ajt.13863","article-title":"Azathioprine and risk of skin cancer in organ transplant recipients: systematic review and meta-analysis","volume":"16","author":"Jiyad","year":"2016","journal-title":"Am J Transplant"},{"issue":"9","key":"10.1016\/j.jaad.2025.05.1401_bib11","doi-asserted-by":"crossref","first-page":"1594","DOI":"10.1093\/rheumatology\/kew214","article-title":"Disease-modifying anti-rheumatic drugs and non-melanoma skin cancer in inflammatory arthritis patients: a retrospective cohort study","volume":"55","author":"Lange","year":"2016","journal-title":"Rheumatology (Oxford)"},{"issue":"2","key":"10.1016\/j.jaad.2025.05.1401_bib12","doi-asserted-by":"crossref","first-page":"164","DOI":"10.1001\/jamadermatol.2015.3029","article-title":"Risk of nonmelanoma skin cancer associated with the use of immunosuppressant and biologic agents in patients with a history of autoimmune disease and nonmelanoma skin cancer","volume":"152","author":"Scott","year":"2016","journal-title":"JAMA Dermatol"},{"issue":"6","key":"10.1016\/j.jaad.2025.05.1401_bib13","doi-asserted-by":"crossref","first-page":"794","DOI":"10.1002\/art.23716","article-title":"Incidence of melanoma and other malignancies among rheumatoid arthritis patients treated with methotrexate","volume":"59","author":"Buchbinder","year":"2008","journal-title":"Arthritis Rheum"},{"key":"10.1016\/j.jaad.2025.05.1401_bib14","article-title":"ARTIS Study Group. Rheumatoid arthritis, anti-tumour necrosis factor treatment, and risk of squamous cell and basal cell skin cancer: cohort study based on nationwide prospectively recorded data from Sweden","volume":"352","author":"Raaschou","year":"2016","journal-title":"BMJ"},{"issue":"3","key":"10.1016\/j.jaad.2025.05.1401_bib15","doi-asserted-by":"crossref","first-page":"769","DOI":"10.1007\/s10067-019-04865-y","article-title":"Risk of non-melanoma skin cancer for rheumatoid arthritis patients receiving TNF antagonist: a systematic review and meta-analysis","volume":"39","author":"Wang","year":"2020","journal-title":"Clin Rheumatol"},{"issue":"4","key":"10.1016\/j.jaad.2025.05.1401_bib16","doi-asserted-by":"crossref","first-page":"752","DOI":"10.1111\/jdv.12675","article-title":"An increased risk of non-melanoma skin cancer during TNF-inhibitor treatment in psoriasis patients compared to rheumatoid arthritis patients probably relates to disease-related factors","volume":"29","author":"van L\u00fcmig","year":"2015","journal-title":"J Eur Acad Dermatol Venereol"},{"key":"10.1016\/j.jaad.2025.05.1401_bib17","doi-asserted-by":"crossref","DOI":"10.1136\/bmj.f1939","article-title":"ARTIS Study Group. Rheumatoid arthritis, anti-tumour necrosis factor therapy, and risk of malignant melanoma: nationwide population based prospective cohort study from Sweden","volume":"346","author":"Raaschou","year":"2013","journal-title":"BMJ"},{"issue":"5","key":"10.1016\/j.jaad.2025.05.1401_bib18","doi-asserted-by":"crossref","first-page":"517","DOI":"10.1097\/CMR.0000000000000284","article-title":"Melanoma risk in patients with rheumatoid arthritis treated with tumour necrosis factor alpha inhibitors: a systematic review and meta-analysis","volume":"26","author":"Olsen","year":"2016","journal-title":"Melanoma Res"},{"issue":"2","key":"10.1016\/j.jaad.2025.05.1401_bib19","doi-asserted-by":"crossref","first-page":"390","DOI":"10.1053\/j.gastro.2012.05.004","article-title":"Risk of melanoma and nonmelanoma skin cancer among patients with inflammatory bowel disease","volume":"143","author":"Long","year":"2012","journal-title":"Gastroenterology"},{"issue":"11","key":"10.1016\/j.jaad.2025.05.1401_bib20","doi-asserted-by":"crossref","first-page":"1895","DOI":"10.1136\/ard.2010.149419","article-title":"Malignancies associated with tumour necrosis factor inhibitors in registries and prospective observational studies: a systematic review and meta-analysis","volume":"70","author":"Mariette","year":"2011","journal-title":"Ann Rheum Dis"},{"issue":"2","key":"10.1016\/j.jaad.2025.05.1401_bib21","doi-asserted-by":"crossref","first-page":"386","DOI":"10.1136\/annrheumdis-2016-209285","article-title":"Risk of invasive melanoma in patients with rheumatoid arthritis treated with biologics: results from a collaborative project of 11 European biologic registers","volume":"76","author":"Mercer","year":"2017","journal-title":"Ann Rheum Dis"},{"issue":"4","key":"10.1016\/j.jaad.2025.05.1401_bib22","doi-asserted-by":"crossref","first-page":"632","DOI":"10.1016\/j.jaad.2016.10.006","article-title":"Malignancy rates in a large cohort of patients with systemically treated psoriasis in a managed care population","volume":"76","author":"Asgari","year":"2017","journal-title":"J Am Acad Dermatol"},{"issue":"7","key":"10.1016\/j.jaad.2025.05.1401_bib23","doi-asserted-by":"crossref","first-page":"787","DOI":"10.1001\/jamadermatol.2020.1300","article-title":"Melanoma risk in patients treated with biologic therapy for common inflammatory diseases: a systematic review and meta-analysis","volume":"156","author":"Esse","year":"2020","journal-title":"JAMA Dermatol"},{"issue":"4","key":"10.1016\/j.jaad.2025.05.1401_bib24","doi-asserted-by":"crossref","first-page":"683","DOI":"10.1093\/rheumatology\/key352","article-title":"Abatacept initiation in rheumatoid arthritis and the risk of cancer: a population-based comparative cohort study","volume":"58","author":"Montastruc","year":"2019","journal-title":"Rheumatology (Oxford)"},{"issue":"9","key":"10.1016\/j.jaad.2025.05.1401_bib25","doi-asserted-by":"crossref","first-page":"2360","DOI":"10.1093\/rheumatology\/kez604","article-title":"Abatacept in rheumatoid arthritis and the risk of cancer: a world observational post-marketing study","volume":"59","author":"de Germay","year":"2020","journal-title":"Rheumatology (Oxford)"},{"issue":"3","key":"10.1016\/j.jaad.2025.05.1401_bib26","doi-asserted-by":"crossref","first-page":"1657","DOI":"10.1007\/s13311-021-01073-y","article-title":"Association between disease-modifying therapies prescribed to persons with multiple sclerosis and cancer: a WHO pharmacovigilance database analysis","volume":"18","author":"Dolladille","year":"2021","journal-title":"Neurotherapeutics"},{"issue":"7","key":"10.1016\/j.jaad.2025.05.1401_bib27","doi-asserted-by":"crossref","first-page":"1541","DOI":"10.1002\/cam4.1098","article-title":"Melanoma complicating treatment with natalizumab for multiple sclerosis: a report from the Southern Network on Adverse Reactions (SONAR)","volume":"6","author":"Sabol","year":"2017","journal-title":"Cancer Med"},{"issue":"3","key":"10.1016\/j.jaad.2025.05.1401_bib28","doi-asserted-by":"crossref","first-page":"363","DOI":"10.1007\/s40257-017-0337-2","article-title":"Malignancy risk and recurrence with psoriasis and its treatments: a concise update","volume":"19","author":"Geller","year":"2018","journal-title":"Am J Clin Dermatol"},{"issue":"8","key":"10.1016\/j.jaad.2025.05.1401_bib29","doi-asserted-by":"crossref","first-page":"1006","DOI":"10.1136\/ard.2005.048371","article-title":"Safety of extended treatment with anakinra in patients with rheumatoid arthritis","volume":"65","author":"Fleischmann","year":"2006","journal-title":"Ann Rheum Dis"},{"issue":"2","key":"10.1016\/j.jaad.2025.05.1401_bib30","doi-asserted-by":"crossref","first-page":"222","DOI":"10.1016\/j.semarthrit.2019.03.002","article-title":"Risk of malignancy associated with use of tocilizumab versus other biologics in patients with rheumatoid arthritis: a multi-database cohort study","volume":"49","author":"Kim","year":"2019","journal-title":"Semin Arthritis Rheum"},{"issue":"6","key":"10.1016\/j.jaad.2025.05.1401_bib31","doi-asserted-by":"crossref","first-page":"1554","DOI":"10.1053\/j.gastro.2020.01.001","article-title":"Safety of Janus kinase inhibitors in patients with inflammatory bowel diseases or other immune-mediated diseases: a systematic review and meta-analysis","volume":"158","author":"Olivera","year":"2020","journal-title":"Gastroenterology"},{"issue":"1","key":"10.1016\/j.jaad.2025.05.1401_bib32","doi-asserted-by":"crossref","first-page":"8","DOI":"10.1186\/s13317-021-00153-5","article-title":"Effect of janus kinase inhibitors and methotrexate combination on malignancy in patients with rheumatoid arthritis: a systematic review and meta-analysis of randomized controlled trials","volume":"12","author":"Solipuram","year":"2021","journal-title":"Auto Immun Highlights"},{"issue":"4","key":"10.1016\/j.jaad.2025.05.1401_bib33","doi-asserted-by":"crossref","first-page":"316","DOI":"10.1056\/NEJMoa2109927","article-title":"Cardiovascular and cancer risk with tofacitinib in rheumatoid arthritis","volume":"386","author":"Ytterberg","year":"2022","journal-title":"N Engl J Med"},{"issue":"2","key":"10.1016\/j.jaad.2025.05.1401_bib34","doi-asserted-by":"crossref","first-page":"11","DOI":"10.1007\/s11864-020-00815-y","article-title":"Janus kinase inhibitors and non-melanoma skin cancer","volume":"22","author":"Greif","year":"2021","journal-title":"Curr Treat Options Oncol"},{"issue":"2","key":"10.1016\/j.jaad.2025.05.1401_bib35","doi-asserted-by":"crossref","first-page":"339","DOI":"10.1016\/j.jaad.2021.10.004","article-title":"A 10-year retrospective cohort study of ruxolitinib and association with nonmelanoma skin cancer in patients with polycythemia vera and myelofibrosis","volume":"86","author":"Lin","year":"2022","journal-title":"J Am Acad Dermatol"},{"issue":"2","key":"10.1016\/j.jaad.2025.05.1401_bib36","doi-asserted-by":"crossref","first-page":"356","DOI":"10.1111\/bjh.17192","article-title":"Second primary malignancy in myelofibrosis patients treated with ruxolitinib","volume":"193","author":"Polverelli","year":"2021","journal-title":"Br J Haematol"},{"issue":"11","key":"10.1016\/j.jaad.2025.05.1401_bib37","doi-asserted-by":"crossref","first-page":"2707","DOI":"10.1007\/s00277-021-04647-0","article-title":"Ruxolitinib-treated polycythemia vera patients and their risk of secondary malignancies","volume":"100","author":"Sekhri","year":"2021","journal-title":"Ann Hematol"},{"issue":"9","key":"10.1016\/j.jaad.2025.05.1401_bib38","doi-asserted-by":"crossref","first-page":"4089","DOI":"10.1002\/cam4.2107","article-title":"Second primary malignancies in postpolycythemia vera and postessential thrombocythemia myelofibrosis: a study on 2233 patients","volume":"8","author":"Mora","year":"2019","journal-title":"Cancer Med"},{"issue":"3","key":"10.1016\/j.jaad.2025.05.1401_bib39","doi-asserted-by":"crossref","first-page":"534","DOI":"10.1016\/j.jaad.2022.11.043","article-title":"Risk of melanoma and nonmelanoma skin cancer with immunosuppressants, part II: methotrexate, alkylating agents, biologics, and small molecule inhibitors","volume":"88","author":"Kreher","year":"2023","journal-title":"J Am Acad Dermatol"},{"issue":"6","key":"10.1016\/j.jaad.2025.05.1401_bib40","doi-asserted-by":"crossref","first-page":"1302","DOI":"10.1016\/j.jaad.2023.08.047","article-title":"Trends and efficacy of empiric antibiotic administration in Mohs micrographic surgery: a global, propensity matched, retrospective cohort study","volume":"89","author":"Lauck","year":"2023","journal-title":"J Am Acad Dermatol"},{"issue":"4","key":"10.1016\/j.jaad.2025.05.1401_bib41","doi-asserted-by":"crossref","first-page":"e535","DOI":"10.1111\/jdv.18700","article-title":"Mortality in eight autoimmune bullous diseases: a global large-scale retrospective cohort study","volume":"37","author":"Boch","year":"2023","journal-title":"J Eur Acad Dermatol Venereol"},{"issue":"2","key":"10.1016\/j.jaad.2025.05.1401_bib42","doi-asserted-by":"crossref","first-page":"388","DOI":"10.1016\/j.jaad.2022.10.031","article-title":"Isotretinoin and the risk of psychiatric disturbances: a global study shedding new light on a debatable story","volume":"88","author":"Kridin","year":"2023","journal-title":"J Am Acad Dermatol"},{"key":"10.1016\/j.jaad.2025.05.1401_bib43","doi-asserted-by":"crossref","DOI":"10.1016\/j.ebiom.2023.104639","article-title":"Cutaneous lupus erythematosus is associated with an increased risk of cardiac and vascular diseases: a large-scale, propensity-matched global retrospective cohort study","volume":"93","author":"Olbrich","year":"2023","journal-title":"EBioMedicine"},{"issue":"5","key":"10.1016\/j.jaad.2025.05.1401_bib44","doi-asserted-by":"crossref","first-page":"1065","DOI":"10.1016\/j.jaad.2024.01.020","article-title":"Adverse events after empiric antibiotic administration in dermatologic surgery: a global, propensity-matched, retrospective cohort study","volume":"90","author":"Lauck","year":"2024","journal-title":"J Am Acad Dermatol"},{"issue":"7","key":"10.1016\/j.jaad.2025.05.1401_bib45","doi-asserted-by":"crossref","first-page":"1559","DOI":"10.1111\/j.1572-0241.2006.00603.x","article-title":"The epidemiology of inflammatory bowel disease in Canada: a population-based study","volume":"101","author":"Bernstein","year":"2006","journal-title":"Am J Gastroenterol"},{"issue":"6","key":"10.1016\/j.jaad.2025.05.1401_bib46","doi-asserted-by":"crossref","first-page":"1576","DOI":"10.1002\/art.27425","article-title":"Is the incidence of rheumatoid arthritis rising?: results from Olmsted County, Minnesota, 1955-2007","volume":"62","author":"Myasoedova","year":"2010","journal-title":"Arthritis Rheum"},{"issue":"4","key":"10.1016\/j.jaad.2025.05.1401_bib47","doi-asserted-by":"crossref","first-page":"731","DOI":"10.1016\/j.jaad.2023.11.039","article-title":"Cutaneous squamous cell carcinoma tumor accrual rates in immunosuppressed patients with autoimmune and inflammatory conditions: a retrospective cohort study","volume":"90","author":"Granger","year":"2024","journal-title":"J Am Acad Dermatol"}],"container-title":["Journal of the American Academy of Dermatology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S019096222502184X?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S019096222502184X?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,8,20]],"date-time":"2025-08-20T00:08:48Z","timestamp":1755648528000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S019096222502184X"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,9]]},"references-count":47,"journal-issue":{"issue":"3","published-print":{"date-parts":[[2025,9]]}},"alternative-id":["S019096222502184X"],"URL":"https:\/\/doi.org\/10.1016\/j.jaad.2025.05.1401","relation":{},"ISSN":["0190-9622"],"issn-type":[{"value":"0190-9622","type":"print"}],"subject":[],"published":{"date-parts":[[2025,9]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Cutaneous malignancy after biologic therapy for inflammatory disease: An active comparator, retrospective cohort study","name":"articletitle","label":"Article Title"},{"value":"Journal of the American Academy of Dermatology","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.jaad.2025.05.1401","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2025 Published by Elsevier Inc. on behalf of the American Academy of Dermatology, Inc.","name":"copyright","label":"Copyright"}]}}